Table 1 Baseline characteristics of the 16 included studies
Study | Region | Follow-up | n PGB/CRL/PLA | Mean age PGB/CRL/PLA | Female PGB/CRL/PLA | Type of TJA | Doses Pregabalina/Control or PLA at day | Administration TIme | COI | Funding |
|---|---|---|---|---|---|---|---|---|---|---|
Buvanendran et al. 2010 [9] | USA | 30 days | 120/120 | 64/63.3 | 91/84 | TKA | 300 mg/PLA | NR | NR | NR |
Carmichael et al. 2013 [33] | Canada | 6 months | 15/16 | 59.1/61.3 | 8/6 | THA | 150 mg/PLA | NR | NR | YES |
Clarke et al. 2015 [10] | Canada | 3 months | 92/92 | 60.2/60.1 | 42/38 | THA | 150 mg/PLA | ≤ 2 h | NR | YES |
Imani et al. 2023 [11] | Iran | 6 months | 20/20/20 | 67.6/65.5/66.8 | 19/20/17 | TKA | 150 mg/60 mg duloxetine/ PLA | ≤ 2 h | No | No |
Jain et al. 2012 [13] | India | 2 days | 20/20 | 59.7/ 57.1 | 11/15 | TKA | 150 mg/NR | ≤ 2 h | No | Yes |
Kadic et al. 2016 [34] | The Netherlands | 3 days | 30/30 | 62.8/ 65.5 | 15/14 | TKA | 150mg < 65 years old or 75mg > 65 years old/PLA | NR | No | No |
Lee et al. 2015 [14] | Korea | 2 days | 21/20 | 63.38/ 67.60 | NR | TKA | 400 mg celecoxib + 150 mg pregabalin/ 400 mg celecoxib | ≤ 2 h | Yes | No |
Lee et al. 2018 [35] | Korea | 1 day | 33/31/31 | 68.4/68.8/67.2 | 15/13 /12 | TKA + THA | dexmedetomidine/150 mg + dexmedetomidine/PLA | NR | NR | NR |
Lubis et al. 2018 [36] | Indonesia | 3 days | 10/10/10 | 66.1/65.9/68.2 | 7/7/9 | TKA | (150 mg + celecoxib 400 mg)/ three times of 150 mg + celecoxib 400 mg/PLA | > 24 h and ≤ 2 h | No | NR |
Martinez et al. 2014 [37] | France-USA | 2 days | 35/34/35/38 | 64/60/59/64 | 15/23/17/13 | THA | 150 mg/ ketamin/ combination/PLA | NR | No | No |
Mathiesen et al. 2008 [38] | Denmark | 1 day | 40/42/38 | 67/68/66 | 26/20/20 | THA | 300 mg/300 mg + 8 mg dexamethasone/PLA | ≤ 2 h | No | Yes |
Niruthisard et al. 2013 [39] | Thailand | 2 days | 25/23/27 | 69/66/67 | 23/22/25 | TKA | 150 mg/ celecoxib 400 mg/PLA | ≤ 2 h | No | Yes |
Singla et al. 2014 [40] | USA | 6 weeks | 98/96/98 | 63.0/63.7/63.3 | 60/61/54 | TKA | 150 mg/300 mg/PLA | 8–12 h | Yes | No |
YaDeau et al. 2015 [12] | USA | 14 days | 30/30/30/30 | 67/65/68/66 | 18/13/23/14 | TKA | 100/200/300 mg/PLA | ≤ 2 h | NR | Yes |
Yik et al. 2019 [41] | Singapure | 6 months | 45/42 | 65.1/66.6 | 31/29 | TKA | 75 mg/PLA | ≤ 2 h | No | No |
Zhou et al. 2023 [42] | China | 2 days | 38/38/37/36 | 64.9/61.5/63.0/62.6 | 30/28/29/27 | TKA | 300 mg/ celecoxib 400 mg/combination or PLA | 8–12 h | No | NR |